Opus Genetics, Inc. approved an equity award for a non-executive employee under their 2021 Inducement Plan. The award consists of options to purchase 50,000 shares of common stock, vesting over four years. Opus Genetics focuses on developing gene therapies to treat inherited retinal diseases, with seven programs in their pipeline. The Company is also working on Phentolamine Ophthalmic Solution 0.75% for various eye conditions. Based in Research Triangle Park, NC, Opus Genetics aims to provide one-time treatments for severe retinal disorders. For more information, visit www.opusgtx.com. Investors and media contacts are provided for further inquiries.

Read more at GlobeNewswire: Opus Genetics Reports Inducement Grant Under Nasdaq Listing